USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SEQUELLA, INC.
Address:
9610 MEDICAL CENTER DR, STE 200
ROCKVILLE, MD
Phone:
N/A
URL:
N/A
EIN:
522044703
DUNS:
125129606
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,918,941.00 19
SBIR Phase II $6,309,125.00 4
STTR Phase I $587,856.00 1

Award List:

ANTIBODY BASED DIAGNOSTIC FOR TB IN NONHUMAN PRIMATES

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Nacy, Carol A
Abstract:
N/a

SHIKIMATE ENZYMES AS NOVEL TUBERCULOSIS DRUG TARGETS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$294,182.00
Agency:
HHS
Principal Investigator:
Jan Dijkstra
Abstract:
Not Available The development of equipment that requires extensive fluid manipulation, such as analytical diagnostic tools, has generally lagged behind those of a purely electromechanical nature, even though obvious demand exists in areas as diverse as medicine, environmental monitoring, food… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Leo Einck
Abstract:
N/a

COMMERCIAL DEVELOPMENT OF THE BRONX BOX

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$294,875.00
Agency:
HHS
Principal Investigator:
Leo Einck
Abstract:
Confirmation of a diagnosis of tuberculosis requires clear identification of the infecting organism. Historically, this has been accomplished by specific staining (i.e. acid fast staining, and recently by specific fluorescent antibody staining) and liquid culture. More recently,… More

A Rapid Lateral Flow Test for TB in Nonhuman Primates

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$162,215.00
Agency:
HHS
Principal Investigator:
Carol A. Nacy
Abstract:
DESCRIPTION (provided by applicant): The goal of the research is to develop a rapid, lateral flow, antibody-based diagnostic test for tuberculosis (TB) in nonhuman primates. The unreliability of the present TB skin test underlies the frequent devastating outbreaks of TB among… More

Transdermal Test for Active Tuberculosis

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$232,038.00
Agency:
HHS
Principal Investigator:
Carol A. Nacy
Abstract:
DESCRIPTION (provided by applicant):This proposal seeks to establish a development program to transition an experimental Transdermal Tuberculosis Skin Test into a commercial product. This technology has already demonstrated a remarkable ability to specifically identify… More

A New Tuberculin for the Diagnosis of Tuberculosis

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Leo Einck
Abstract:
DESCRIPTION (provided by applicant):Accurate diagnosis of tuberculosis (TB) infection is one of the pillars of effective TB control programs. The current tool to diagnose infection with Mycobacterium tuberculosis is the tuberculin skin test (TST). Because of the… More

TRANSDERMAL, NON-INVASIVE MONITORING OF MEDICATION INGESTION

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$99,896.00
Agency:
HHS
Principal Investigator:
Katherine Sacksteder
Abstract:
N/a

COMMERCIAL DEVELOPMENT OF THE BRONX BOX

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$1,064,900.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The World Health Organization (WHO) estimates that globally there are approximately 50 million people with multi-drug resistant tuberculosis (MDR-TB). Recognizing this threat, public health agencies throughout the world have emphasized the importance of… More

COMMERCIAL DEVELOPMENT OF THE BRONX BOX

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The World Health Organization (WHO) estimates that globally there are approximately 50 million people with multi-drug resistant tuberculosis (MDR-TB). Recognizing this threat, public health agencies throughout the world have emphasized the importance of… More

A Rapid Lateral Flow Test for TB in Nonhuman Primates

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to develop and bring to market a new diagnostic test for tuberculosis (TB) in nonhuman primates. The new diagnostic is based upon the detection, in infected animals, of antibodies to a set of recombinant TB antigens. The proposed… More

A Rapid Lateral Flow Test for TB in Nonhuman Primates

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$1,972,752.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to develop and bring to market a new diagnostic test for tuberculosis (TB) in nonhuman primates. The new diagnostic is based upon the detection, in infected animals, of antibodies to a set of recombinant TB antigens. The proposed… More

BCG + hsp, a New Tuberculosis Vaccine

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$299,045.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This proposal describes research that will examine the safety and efficacy of a novel strain of BCG in which the heat shock repressor gene has been deleted, resulting in the overexpression of a heat shock protein (hsp70). Heat shock proteins show a good deal of… More

N/A

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Katherine Sacksteder
Abstract:
N/a

N/A

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$939,150.00
Agency:
HHS
Principal Investigator:
Katherine Sacksteder
Abstract:
N/a

Dipiperidines as a new class of anti-TB drug

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$299,475.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall aim of this application is to characterize a new class of drugs to treat tuberculosis (TB) that are structurally unrelated to any existing anti-TB drugs. Three years ago, Sequella received a Challenge grant to synthesize and characterize… More

Novel mycobacterial translocase I inhibitors--a new class of anti-TB drugs

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$228,016.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent statistics lists tuberculosis (TB) as a serious infectious disease that kills nearly 2 million people worldwide each year. One third of the world's population is infected with the bacterial pathogen, M. tuberculosis (Mtb) that causes TB. HIV/AIDs increases… More

Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$2,332,323.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Physicians treating tuberculosis (TB) today are in desperate need of new, efficient, and effective antibiotics to improve both time of treatment and durability of cure in multi-drug resistant (MDR) as well as uncomplica ted TB. In the completed Phase 1 grant… More

Development of a phage-based nucleic acid amplification diagnostic for the rapid

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$244,346.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In April 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global health emergency, a distinction never accorded another disease. Two billion people are infected with Mycobacterium tuberculosis (Mtb ), leading to eight million new TB cases… More

Advancing lead dipiperidine compound into preclinical development

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$305,054.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In our previous work we identified a series of potent cell-wall inhibiting dipiperidines that are structurally unrelated to any existing antitubercular drugs. After extensive analysis of the lead molecules for anim- icr obial activity and drug properties compound… More

SQ641, new drug candidate to treat NTM infections

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$594,661.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Mycobacterium avium complex (MAC) and M. abscessus (MAB) are the two most common nontuberculous mycobacteria (NTM) that cause human disease, and the incidence of NTM infections has been increasing worldwide. Both the or ganisms are generally resistant to standard… More

SQ109 for treatment of MDR-TB

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$599,797.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): SQ109 is a small molecule, orally active drug and is a new drug candidate in clinical development for the treatment of all forms of tuberculosis (TB), including multi-drug resistant (MDR) and extreme drug resistant (XDR ) TB. SQ109 has a unique pharmacological… More

Targeting MtrAB of M. tuberculosis

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$587,856.00
Agency:
HHS
Principal Investigator:
Marina N. Protopopova – 301-217-3832
Research Institution:
UNIVERSITY OF WASHINGTON
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Tuberculosis (TB) has a massive impact on global health. The World Health Organization estimates that one- third of all people worldwide harbor latent TB infections, with sixteen million cases of active disease and nearly two million deaths caused by… More

A New Therapeutic Regimen for MDR-TB

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$565,341.00
Agency:
HHS
Principal Investigator:
Carol A. Nacy – 301-762-7776
Abstract:
DESCRIPTION (provided by applicant): World Health Organization (WHO) declared tuberculosis (TB) a global health emergency; a distinction never accorded another disease. Two billion people are infected with Mycobacterium tuberculosis (Mtb) worldwide, leading to over 9 million new TB cases each year… More